Stockscreener 앱 받기
0.0005
0.00%
0.00
전일 마감가:
$0.0005
열려 있는:
$0.0008
하루 거래량:
13,952
Relative Volume:
1.77
시가총액:
$N/A
수익:
$9.94M
순이익/손실:
$-97.82M
주가수익비율:
-0.000163
EPS:
-3.07
순현금흐름:
$-100.02M
1주 성능:
+0.00%
1개월 성능:
-90.00%
6개월 성능:
-97.73%
1년 성능:
-99.50%
1일 변동 폭
$0.0005
$0.0008
1주일 범위
$0.0005
$0.0008
52주 변동 폭
$0.0005
$0.0282
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
SYRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.0005 | 0 | 9.94M | -97.82M | -100.02M | -3.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-11-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-08 | 재개 | JMP Securities | Mkt Outperform |
| 2019-02-14 | 재개 | Oppenheimer | Outperform |
| 2018-11-05 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2018-03-13 | 재확인 | Wedbush | Outperform |
| 2017-10-31 | 재개 | Piper Jaffray | Overweight |
| 2017-10-23 | 개시 | ROTH Capital | Neutral |
| 2017-08-10 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
모두보기
Syros Pharmaceuticals Inc 주식(SYRS)의 최신 뉴스
Reviewing Vectura Group (OTCMKTS:VEGPF) and Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Head-To-Head Review: Aerovate Therapeutics (NASDAQ:AVTE) vs. Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
SYRS (Syros Pharmaceuticals) Price-to-Tangible-Book : (As of Oct. 22, 2025) - GuruFocus
CapEx per share of Syros Pharmaceuticals, Inc. – OTC:SYRS - TradingView
Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN
Net current asset value per share of Syros Pharmaceuticals, Inc. – OTC:SYRS - TradingView
JMP Securities Downgrades Syros Pharmaceuticals (SYRS) - MSN
Myelodysplastic Syndrome Pipeline Analysis, 2025 by DelveInsight | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, - Barchart.com
Syros Pharmaceuticals, Inc. (SYRS) stock price, news, quote and history - Yahoo Finance Singapore
Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $3.33 - Defense World
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital - The Manila Times
Syros Pharmaceuticals (SYRS) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus
Syros Pharma pulls out of deal with RaQualia - The Pharma Letter
SYRS Stock Price and Chart — OTC:SYRS - TradingView
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com
Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY) - Benzinga
Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations - Stock Titan
Syros Pharmaceuticals stock plunges to 52-week low of $0.16 - Investing.com
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - Investing.com Canada
Odyssey hires Jason Haas as CFO - biocentury.com
Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com
Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - Nasdaq
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - Yahoo Finance
Syros stock craters after lead cancer therapy flops in Phase III trial - Pharmaceutical Technology
Syros stock dives 92% on failed Phase 3 study, possible loan default (NASDAQ:SYRS) - Seeking Alpha
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update - Business Wire
Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
CDK 7 Inhibitors Market is Expected to Showcase a Significant Growth by 2034 | DelveInsight - The Malaysian Reserve
Syros Pharmaceuticals Chief Financial Officer Acquires 407% More Stock - simplywall.st
Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) - Yahoo Finance
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gew - GuruFocus
Syros Pharmaceuticals, Inc. (SYRS) Investigation: - GlobeNewswire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings - Business Wire
How to contact the Daily Bulletin - FinancialContent
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - PR Newswire
Syros Pharma tanks as it updates on SELECT-AML-1 study | Biotechnology | The Pharmaletter - The Pharma Letter
Why Is Syros Pharmaceuticals (SYRS) Stock Down 62% Today? - TradingView — Track All Markets
Syros ending enrollment in phase 2 leukemia study - Seeking Alpha
Syros Pharmaceuticals Inc (SYRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.62%
자본화:
|
볼륨(24시간):